Long‐term follow‐up of patients with uterine fibroids after treatment with the LHRH agonist buserelin

摘要: Summary. Ten patients with uterine fibroids palpable abdominally were treated the luteinizing hormone-releasing hormone (LHRH) agonist buserelin, administered intransally, 300 μg three times daily, for 6 months, and then followed a further 12 months. Oestrogen levels markedly reduced in all during treatment. At end of treatment mean volume reductions 44·4% (SEM 3·5) total 57·3% 7·4) discrete as assessed ultrasonically. There was also marked improvement associated symptoms. After buserelin therapy stopped, fibroid volumes returned to, or slightly exceeded, pretreatment within months five patients, by two patients. Three other who underwent surgery their first 4 after showed regrowth to size, Four comparable asymptomtic untreated no significant change six monthly ultrasonic assessments. Buserelin may facilitate rather than replace management fibroids.